ERBB2 and breast carcinoma: To study the kinetics of proteostatic perturbations during the cellular adaptation to chronic Her2 inhibition, we followed a frequently employed in vitro approach to the modeling of acquired resistance by prolonged incubation of Her2-amplified SKBR3 breast cancer cells in increasing doses of lapatinib (Fig 1A).